The Mid-Day Buzz
Novo Nordisk Shares Rise After Positive Phase 3 Trial Results for Experimental Weight-Loss Injection Cagrilintide, Offering New Hope in Obesity Treatment Market
Wegovy Trial Data Lifts Novo Nordisk as U.S. Market Challenges Weigh on Growth
Viking Therapeutics Shares Tumble 40% After Midstage Obesity Pill Trial Disappoints Investors
GoodRx Stock Surges After Novo Nordisk GLP-1 Deal at $499/Month
The Mid-Day Buzz
Trump Issues Ultimatum to Pharma CEOs: Cut Drug Prices Within 60 Days or Face Action
Novo Nordisk Stock Craters as Wegovy and Ozempic Forecasts Get Slashed
The Mid-Day Buzz
Novo Nordisk Stock Drops After Disappointing Weight-Loss Drug Trial and Hims & Hers Fallout
Pump Radar
Stock Alerts